Replies to post #140570 on Biotech Values

[oc631]

So you're saying you only think GS-7977+ one other HCV DAA will be necessary even in absence of ribavirin?

IMO if GILD goes with a best-in-class drug, in combination with GS-7977, Riba won't be required to achieve approval in GT1 patients. Perhaps Riba as a third agent can overcome shortcomings in efficacy (if any) of GILD using an in-house combination.